SS-31 10 mg

SS-31 (Elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) designed specifically for research involving mitochondrial structure and function. This peptide is known for its unique ability to interact selectively with cardiolipin, a phospholipid located within the inner mitochondrial membrane that is essential for electron transport chain function and ATP synthesis. SS-31 concentrates in mitochondria at 1000-5000x the extracellular concentration, making it one of the most targeted mitochondrial compounds in research.

SS-31 was developed by Dr. Hazel Szeto and Dr. Peter Bhatt at Weill Cornell Medical College as part of a series of Szeto-Schiller peptides designed to target mitochondria. The key breakthrough was discovering that alternating aromatic and basic amino acid motifs allow peptides to cross membranes and concentrate in mitochondria independent of membrane potential. SS-31 (also known as MTP-131 and Elamipretide) advanced to clinical trials for conditions involving mitochondrial dysfunction, including Barth syndrome, heart failure, and age-related macular degeneration.

Key Areas:

• Mitochondrial Membrane Stabilization — SS-31 selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae architecture and optimizing electron transport chain efficiency.
• Oxidative Stress Reduction — By stabilizing the electron transport chain, SS-31 reduces electron leak and subsequent ROS production — addressing oxidative stress at its source.
• Cardiac Function — Clinical trials have evaluated SS-31 in heart failure patients, showing improvements in left ventricular function and exercise capacity.
• Neurodegeneration — Preclinical studies demonstrate SS-31's neuroprotective effects in models of Alzheimer's, Parkinson's, and ALS.

SS-31 represents a paradigm shift in mitochondrial medicine — rather than neutralizing damage after it occurs, it prevents dysfunction at the organelle level by stabilizing the core architecture that enables cellular energy production.